{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-131792","form_type":"8-K","ticker":"LXEO","cik":"0001907108","company_name":"Lexeo Therapeutics, Inc.","filed_at":"2026-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.734902+00:00","generated_at":"2026-05-15T08:27:21.856188+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lexeo reports FY2025 net loss $100M; cash $246.6M, runway into 2028; LX2006 pivotal trial on track for 1H2026","bullets":["Net loss FY2025 $100.0M ($1.86/share) vs $98.3M ($3.09/share) in FY2024; Q4 loss $20.9M ($0.27).","R&D expenses FY2025 $63.8M vs $74.1M in FY2024; G&A $45.5M vs $31.7M.","Cash $246.6M as of Dec 31, 2025, expected to fund operations into 2028.","LX2006 for FA: FDA feedback on SUNRISE-FA 2 pivotal protocol expected Q2 2026; trial start 1H 2026.","Collaboration with Johnson & Johnson for targeted cardiac AAV delivery; new CMO Dr. Narinder Bhalla appointed."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-131792","json":"https://secwatch.observer/filing/0001193125-26-131792.json","markdown":"https://secwatch.observer/filing/0001193125-26-131792.md","text":"https://secwatch.observer/filing/0001193125-26-131792.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1907108/000119312526131792/0001193125-26-131792-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1907108/000119312526131792/lxeo-20260330.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:27:21.856188+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d38024108a706a75b885de17bf403946cd59b6bf","claim":"Lexeo Therapeutics, Inc. reported financial results for the fourth quarter and full year 2025.","evidence_excerpt":"On March 30, 2026, Lexeo Therapeutics, Inc. (the “ Company ”) issued a press release announcing business highlights and its financial results for the three and twelve months ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1907108/000119312526131792/0001193125-26-131792-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}